tbuckley/cabot-search huggingface dataset:
ACTR-32. A PROSPECTIVE PHASE II STUDY OF EVEROLIMUS FOR RECURRENT ADULT LOW GRADE GLIOMAS
Authors: Michael Wahl, Susan Chang, Joanna Phillips, Joseph Costello, Tali Mazor, Annette Molinaro, Janine Lupo, Sarah Nelson, Mitchel S. Berger, Michael Prados, Nicholas Butowski, Jennie Taylor, Jennifer Clarke, Daphne Haas-Kogan
Journal: Neuro-Oncology (2016)

Systemic therapy plays an increasingly important role in management of low-grade gliomas (LGG). Most LGGs demonstrate PI3K/mTOR pathway activation, raising the possibility of benefit from treatment with mTOR inhibitors, including everolimus. 58 adult patients with histologically confirmed recurrence after an initial diagnosis of LGG were treated with daily everolimus for 1 year or until progression. Tissue was acquired within 4 months prior to initiating everolimus. 38 patients underwent serial multiparametric MRIs assessing tumor volume and perfusion metrics (vascular permeability, Kps; capillary density, fBV). Patients received substantial prior treatment, including radiotherapy (59%) and chemotherapy (79%); 19% of patients underwent transformation to WHO grade III or IV pathology before enrollment. The 6-month progression-free survival rate was 87% and 55% for patients with WHO grade II and III/IV pathology, respectively, meeting the primary study endpoint (p<0.001 for improvement from historical rate of 17% for WHO II pathology). With median follow-up of 3.5 years, the median PFS was 1.4 years (95% CI 1.2 – 1.9 years) and 0.6 years (95% CI 0.1 years – NA), while median OS was not reached (95% lower CI, 4.0 years) and 2.9 years (95% CI 1.6 years – NA), for WHO II and III/IV, respectively. 27 patients (46%) completed one year of treatment without progression. Significant decrease in fBV and Kps was observed after 6 months (p=0.04 and p=0.008, respectively), and was associated with improved PFS (p=0.004 and p=0.005, for Kps and fBV, respectively). Molecular markers including PI3K pathway activation are being analyzed and will be available for the conference. Heavily pretreated patients with recurrent LGG undergoing therapy with everolimus demonstrate a high rate of disease stability during treatment. Decreased tumor perfusion during treatment is consistent with antiangiogenic properties of mTOR inhibitors, and could be used as an early radiographic marker of response.
Karyotype Results From CpG Oligodeoxynucleotide Stimulated Chronic Lymphocytic Leukemia (CLL) Cultures Are Consistent Among Laboratories: a CLL Research Consortium (CRC) Study.
Authors: Nyla A. Heerema, John C. Byrd, Paola Dal Cin, Marie L Dell' Aquila, Prasad Koduru, Ayala Aviram, Stephanie Smoley, Laura Z. Rassenti, Andrew Greaves, Jennifer R Brown, Kanti R Rai, Thomas J. Kipps, Neil E. Kay, Daniel van Dyke
Journal: Blood (2009)
Opioids and adverse outcomes in elderly chronic obstructive pulmonary disease patients
Authors: Nicholas T. Vozoris, Denis E. O'Donnell, Sudeep S. Gill
Journal: European Respiratory Journal (2016)

We thank D. Viglino and M. Maignan for their interest in our manuscript [1] and for their insightful comments. They raise a valid point that our mortality results may have been influenced by the potentially confounding effects of palliative care receipt on or following the index date. While we excluded individuals receiving palliative care in the year prior to the index date, we did not do so on or after the index date for practical methodological reasons. However, several points should be considered. First, Viglino and Maignan write that the decision to palliate in chronic obstructive pulmonary disease (COPD) often arises in the context of an acute respiratory exacerbation. Our propensity score model included whether or not a recent acute respiratory exacerbation occurred in the 30 days prior to the index date, and opioid users and nonusers were well balanced on that variable after propensity score weighting [1]. Second, increased respiratory-related and all-cause mortality were found not only among users of opioid-only agents but also among users of combination opioid/nonopioid formulations [1]. Opioids combined with paracetamol or aspirin are unlikely to be used for purposes of palliation and such agents represent ∼90% of incident opioid use among older adults with COPD [2]. Third, while the possible residual inclusion of individuals receiving palliative care among opioid users may potentially explain the finding of increased mortality, this would be unlikely to explain why risks of outpatient respiratory exacerbations and emergency visits for COPD or pneumonia were also greater among opioid users. If there was residual inclusion of individuals with recent end-of-life decisions among opioid users in our study, this would have been likely to bias the intensive care admission outcome towards being significantly decreased among opioid users, and not rendered a nonsignificant association, as Viglino and Maignan propose. Adverse respiratory outcomes are associated with incident opioid drug use among older adults with COPD <http://ow.ly/kGTL304qEe5>
A Photosensitizer Verteporfin Has Light-Independent Anti-Leukemic Activity for Ph-Positive Acute Lymphoblastic Leukemia and Synergistically Works with Dasatinib in Vivo
Authors: Takanobu Morishita, Fumihiko Hayakawa, Keiki Sugimoto, Daiki Hirano, Yuki Kojima, Naoto Imoto, Yuichiro Inagaki, Tomoki Naoe, Hitoshi Kiyoi
Journal: Blood (2015)
Outcome with the Hyper-CVAD and Rituximab Regimen in Burkitt (BL) and Burkitt-Like (BLL) Leukemia/Lymphoma.
Authors: Deborah A. Thomas, Jorge Cortes, Stefan Faderl, Susan O’Brien, Miloslav Beran, Charles Koller, Guillermo Garcia-Manero, Anas Younes, Luis Fayad, William Wierda, Sherry Pierce, Francis J. Giles, Hagop Kantarjian
Journal: Blood (2004)
Treatment Outcome of Discontinued L-Asparaginase in Children with Standard-Risk Acute Lymphoblastic Leukemia: Tokyo Children’s Cancer Study Group (TCCSG) Study L99-15.
Authors: Chitose Ogawa, Akira Ohara, Atsushi Manabe, Ryoji Hanada, Hiroyuki Takahashi, Katsuyoshi Koh, Michiko Kajiwara, Miho Maeda, Kenichi Sugita, Akira Kikuchi, Keiichi Isoyama, Yasushi Noguchi, Masahiro Saito, Setsuo Ota, Takashi Fukushima, Hiromasa Yabe, Yasunori Toyoda, Tomohiro Saito, Mahiro Tsuchida
Journal: Blood (2005)
Defibrotide Low-Dose Continuous Infusion from Day +1 Until Day +21 after Allogeneic Stem Cell Transplantation as Prophylaxis of Veno-Occlusive Disease (VOD) of the Liver. A Single Centre Experience.
Authors: Alessandro Bonini, Paolo Avanzini, Luciano Masini, Francesco Merli, Fiorella Ilariucci, Barbara Gamberi, Alessia Tieghi, Isabel Alvarez, Annalisa Immovilli, Annalisa Pilia, Luigi Gugliotta
Journal: Blood (2007)
Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline
Authors: Erik P. Sulman, Nofisat Ismaila, Terri S. Armstrong, Christina Tsien, Tracy T. Batchelor, Tim Cloughesy, Evanthia Galanis, Mark Gilbert, Vinai Gondi, Mary Lovely, Minesh Mehta, Matthew P. Mumber, Andrew Sloan, Susan M. Chang
Journal: Journal of Clinical Oncology (2017)

Purpose The American Society for Radiation Oncology (ASTRO) produced an evidence-based guideline on radiation therapy for glioblastoma. Because of its relevance to the ASCO membership, ASCO reviewed the guideline and applied a set of procedures and policies used to critically examine guidelines developed by other organizations. Methods The ASTRO guideline on radiation therapy for glioblastoma was reviewed for developmental rigor by methodologists. An ASCO endorsement panel updated the literature search and reviewed the content and recommendations. Results The ASCO endorsement panel determined that the recommendations from the ASTRO guideline, published in 2016, are clear, thorough, and based on current scientific evidence. ASCO endorsed the ASTRO guideline on radiation therapy for glioblastoma and added qualifying statements. Recommendations Partial-brain fractionated radiotherapy with concurrent and adjuvant temozolomide is the standard of care after biopsy or resection of newly diagnosed glioblastoma in patients up to 70 years of age. Hypofractionated radiotherapy for elderly patients with fair to good performance status is appropriate. The addition of concurrent and adjuvant temozolomide to hypofractionated radiotherapy seems to be safe and efficacious without impairing quality of life for elderly patients with good performance status. Reasonable options for patients with poor performance status include hypofractionated radiotherapy alone, temozolomide alone, or best supportive care. Focal reirradiation represents an option for select patients with recurrent glioblastoma, although this is not supported by prospective randomized evidence. Additional information is available at www.asco.org/glioblastoma-radiotherapy-endorsement and www.asco.org/guidelineswiki .
LP51 : Treatment of severe HCV recurrence after liver transplantation with sofosbuvir based regimen: Results of the aisf-sofolt Italian compassionate use program
Authors: P. Andreone, F. Conti, R. Vukotic, S. Fagiuoli, M.C. Morelli, L. Pasulo, M. Colpani, S. Berardi, F.G. Foschi, P. Pianta, M.F. Donato, F. Malinverno, G. Mazzella, M. Tamè, L.S. Belli, R. Viganò, P. Carrai, P. Burra, F.P. Russo, I. Lenci, P. Toniutto, M. Merli, L. Loiacono, R.M. Iemmolo, A. Degli Antoni, A. Romano, A. Picciotto, M. Rendina
Journal: Journal of Hepatology (2015)
Incidence, Risk Factors, and Outcomes of Colorectal Cancer in Patients With Ulcerative Colitis With Low-Grade Dysplasia: A Systematic Review and Meta-analysis
Authors: Mathurin Fumery, Parambir S. Dulai, Samir Gupta, Larry J. Prokop, Sonia Ramamoorthy, William J. Sandborn, Siddharth Singh
Journal: Clinical Gastroenterology and Hepatology (2016)
The Follicular Lymphoma International Prognostic Index (FLIPI) Is Superior to WHO/REAL Histological Grade for Identifying High-Risk Patients: A Retrospective Review of the MSKCC Experience in 260 patients with Follicular Lymphoma.
Authors: Jeffrey L. Halaas, Julie Teruya-Feldstein, Daniel A. Filippa, Moskowitz Chaya, Kikkeri N. Naresh, Andrew D. Zelenetz
Journal: Blood (2004)
Non Hodgkin’s Lymphoma (NHL) and Deep Vein Thrombosis (DVT): A Dangerous Liaison Still Unexplored.
Authors: Giulio Giordano, Silvia Piano, Roberto Marra, Valerio De Stefano, Stefan Hohaus, Licia Iacoviello, Giuseppe Leone, Maria Benedetta Donati, Sergio Storti
Journal: Blood (2007)
Event-Free Survival in Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with 2nd Generation Tyrosine Kinase Inhibitors (TKI) after Imatinib Failure Is Dependent on the In Vitro Sensitivity of BCR-ABL Kinase Domain (KD) Mutations.
Authors: Elias Jabbour, Hagop Kantarjian, Dan Jones, Constantine Tam, Charles Koller, Gautam Borthakur, William Wierda, Jorge Cortes
Journal: Blood (2007)
Clinical Outcomes in Patients Receiving Venous Thromboembolism (VTE) Prophylaxis after Orthopedic Surgery (OS). A Systematic Review and Meta-Analysis of Proportions.
Authors: Alejandro Lazo-Langner, Douglas Coyle, Nicholas J. Barrowman, Tim Ramsay, Philip S. Wells, Dimitrios Scarvelis, Melissa A. Forgie, Marc Rodger
Journal: Blood (2006)
Adverse Prognosis in Acute Myeloid Leukemia with Abnormality Abn(3q): Does EVI1 Matter?
Authors: Theresa Kretschmann, Christoph Röllig, Brigitte Mohr, Michael Kramer, Matthias Stelljes, Martin Kaufmann, Kerstin Schäfer-Eckart, Claudia D. Baldus, Alwin Krämer, Hermann Einsele, Mathias Hänel, Regina Herbst, Stefan W. Krause, Andreas Neubauer, Kristina Sohlbach, Martin Bornhäuser, Christian Thiede, Wolfgang E. Berdel, Hubert Serve, Johannes Schetelig, Gerhard Ehninger, Friedrich Stölzel
Journal: Blood (2015)
Pegylated G-CSF Mobilizes CD34+ Cells with Different Stem and Progenitor Cell Subsets and Distinct Functional Properties in Comparison with Unconjugated G-CSF.
Authors: Ingmar Bruns, Ulrich Steidl, Johannes C. Fischer, Sascha Raschke, Guido Kobbe, Roland Fenk, Michael Rosskopf, Sabrina Pechtel, Ulrich-Peter Rohr, Arndt von Haeseler, Peter Wernet, Daniel Tenen, Rainer Haas, Ralf Kronenwett
Journal: Blood (2006)
Novel Histone Deacetilase (HDAC) Inhibitors: In Vitro Effects on Leukemic Cells
Authors: Maria Rosaria Ricciardi, Roberto Licchetta, Paola Bergamo, Stefano Iacovelli, Andrea Miele, Maria Teresa Petrucci, Michele Milella, Claudio Pisano, Agostino Tafuri
Journal: Blood (2010)
EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients
Authors: Natalia Sutiman, Shao Weng Tan, Eng Huat Tan, Wan Teck Lim, Ravindran Kanesvaran, Quan Sing Ng, Amit Jain, Mei Kim Ang, Wan Ling Tan, Chee Keong Toh, Balram Chowbay
Journal: Journal of Thoracic Oncology (2016)
RASGRP1/APTX Ratio Is a Strong Biomarker of Clinical Response and Survival In AML Patients Treated with Tipifarnib: A Phase I-II Preliminary Results
Authors: Giovanni Martinelli, Emanuela Ottaviani, Stefania Paolini, Cristina Papayannidis, Antonio Curti, Sarah Parisi, Ilaria Iacobucci, Daniela Cilloni, Francesca Arruga, Giuseppe Saglio, Domenico Russo, Giuseppe Visani, Alfonso Zaccaria, Michela Rondoni, Monica Bocchia, Anna Candoni, Renato Fanin, Filippo Gherlinzoni, Michele Baccarani
Journal: Blood (2010)
A Novel Subgroup of Poor Prognostic AML with Low CEBPA Expression, CEBPA Promoter Hypermethylation and DNMT3b Overexpression.
Authors: Hendrik Rudolpf Delwel, Claudia Erpelinck, Roel Verhaak, Ivo P. Touw, Bob Lowenberg, Peter J.M. Valk
Journal: Blood (2004)
Iron Parameters in 84 MDS Patients Enrolled in a Deferasirox (Exjade®, ICL670) Multicenter Trial.
Authors: Alan F. List, Jason Esposito, Jodie Decker, Maria R. Baer, Bayard Powell, David Steensma, Azra Raza, Howard Terebelo, Jaroslaw Maciejewski, Stuart L. Goldberg, Carole Paley
Journal: Blood (2006)
Doctors need dragging out of their comfort zone to avert the antimicrobial crisis, says lord
Authors: Joe Freer
Journal: BMJ (2016)

Doctors need “dragging out of their comfort zone” and should be using highly sensitive diagnostic tests rather than relying on an “educated guess” when prescribing antibiotics, Jim O’Neill, former commercial secretary to the Treasury, has said. The action is needed to avert the predicted 10 million annual deaths and $100 trillion (£80 trillion; €95 trillion) loss to global gross domestic product from antimicrobial resistance by 2050, he said.

O’Neill, who chaired a review on antimicrobial resistance earlier this year,1 was answering questions from MPs on the science and technology select committee …
Selected IL-21R Expression and Apoptosis Induction by IL-21 in Follicular Lymphoma.
Authors: Norihiko Akamatsu, Hiroo Hasegawa, Yasuaki Yamada, Koki Makabe, Ryutaro Asano, Izumi Kumagai, Ken Murata, Kunihiro Tsukasaki, Masao Tomonaga, Kazuto Tsuruda, Kazuyuki Sugahara, Shimeru Kamihira
Journal: Blood (2004)
Time to Minimal Residual Disease (MRD) Negativity Is Independently Predictive of Outcome in Adults with Acute Lymphoblastic Leukemia (ALL) Receiving Hyper-CVAD
Authors: Ryan D. Cassaday, Philip A. Stevenson, Brent L. Wood, Pamela S. Becker, Paul C. Hendrie, Brenda M. Sandmaier, Jerald P. Radich, Andrei R. Shustov
Journal: Blood (2015)
Pfizer could face large fine over pricing of generic phenytoin
Authors: Nigel Hawkes
Journal: BMJ (2016)

The pharmaceutical company Pfizer could face a fine of millions of pounds from the Competition and Markets Authority (CMA), which has been investigating the prices charged for a generic drug used to treat epilepsy.

Court papers seen by the Times shed new light on a deal in which Pfizer agreed to supply the drug to a generic company, Flynn Pharma, at a much greater price than it had been charging the NHS.1 Flynn could then increase the price still further by selling it under the generic name phenytoin sodium. Both companies would benefit, at the cost of the NHS.2

The papers seen by the Times relate to a case brought by another generic company, Tor Generics, which had approached Pfizer with a similar scheme in …
Thromboprophylaxis after Knee Arthroscopy and Lower-Leg Casting
Authors: Raymond A. van Adrichem, Banne Nemeth, Ale Algra, Saskia le Cessie, Frits R. Rosendaal, Inger B. Schipper, Rob G.H.H. Nelissen, Suzanne C. Cannegieter
Journal: New England Journal of Medicine (2016)

The use of thromboprophylaxis to prevent clinically apparent venous thromboembolism after knee arthroscopy or casting of the lower leg is disputed. We compared the incidence of symptomatic venous thromboembolism after these procedures between patients who received anticoagulant therapy and those who received no anticoagulant therapy.We conducted two parallel, pragmatic, multicenter, randomized, controlled, open-label trials with blinded outcome evaluation: the POT-KAST trial, which included patients undergoing knee arthroscopy, and the POT-CAST trial, which included patients treated with casting of the lower leg. Patients were assigned to receive either a prophylactic dose of low-molecular-weight heparin (for the 8 days after arthroscopy in the POT-KAST trial or during the full period of immobilization due to casting in the POT-CAST trial) or no anticoagulant therapy. The primary outcomes were the cumulative incidences of symptomatic venous thromboembolism and major bleeding within 3 months after the procedure.In the POT-KAST trial, 1543 patients underwent randomization, of whom 1451 were included in the intention-to-treat population. Venous thromboembolism occurred in 5 of the 731 patients (0.7%) in the treatment group and in 3 of the 720 patients (0.4%) in the control group (relative risk, 1.6; 95% confidence interval [CI], 0.4 to 6.8; absolute difference in risk, 0.3 percentage points; 95% CI, -0.6 to 1.2). Major bleeding occurred in 1 patient (0.1%) in the treatment group and in 1 (0.1%) in the control group (absolute difference in risk, 0 percentage points; 95% CI, -0.6 to 0.7). In the POT-CAST trial, 1519 patients underwent randomization, of whom 1435 were included in the intention-to-treat population. Venous thromboembolism occurred in 10 of the 719 patients (1.4%) in the treatment group and in 13 of the 716 patients (1.8%) in the control group (relative risk, 0.8; 95% CI, 0.3 to 1.7; absolute difference in risk, -0.4 percentage points; 95% CI, -1.8 to 1.0). No major bleeding events occurred. In both trials, the most common adverse event was infection.The results of our trials showed that prophylaxis with low-molecular-weight heparin for the 8 days after knee arthroscopy or during the full period of immobilization due to casting was not effective for the prevention of symptomatic venous thromboembolism. (Funded by the Netherlands Organization for Health Research and Development; POT-KAST and POT-CAST ClinicalTrials.gov numbers, NCT01542723 and NCT01542762 , respectively.).
Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan
Authors: Wataru Fukuda, Tadamasa Hanyu, Masaki Katayama, Shinichi Mizuki, Akitomo Okada, Masayuki Miyata, Yuichi Handa, Masatoshi Hayashi, Yoshinobu Koyama, Kaoru Arii, Toshiyuki Kitaori, Hiroyuki Hagiyama, Yoshinori Urushidani, Takahito Yamasaki, Yoshihiko Ikeno, Tsuyoshi Suzuki, Atsushi Omoto, Toshifumi Sugitani, Satoshi Morita, Shigeko Inokuma
Journal: Annals of the Rheumatic Diseases (2016)

Although the reactivation of hepatitis B virus (HBV) is recognised as a serious complication in patients with rheumatic disease (RD) receiving immunosuppressive drugs (ISDs), the incidence and risk factors for reactivation remain controversial.To investigate the incidence and risk factors for HBV reactivation in patients with RD.We performed a multicentre, observational, prospective study over 2 years in patients with resolved HBV infection. Patients with RD treated with a dose of ≥5 mg/day prednisolone and/or synthetic or biological ISDs with negative HB virus surface antigen and positive anti-HB virus surface antibody (HBsAb) and/or anti-HB virus core antibody (HBcAb) were enrolled. Quantitative HBV DNA results and related data were regularly recorded.Among 1042 patients, including 959 with rheumatoid arthritis, HBV DNA was detected in 35 (1.93/100 person-years), with >2.1 log copies/mL observed in 10 patients (0.55/100 person-years). None of the reactivated patients, including seven treated with a nucleic acid analogue, showed overt hepatitis. Low HBsAb titres and advanced age seemed to be risk factors for HBV reactivation; however, reactivation was observed in three patients with positive HBsAb and negative HBcAb test results. The risk of reactivation was lower with methotrexate but higher with prednisolone among the different types of ISDs. The intervals from the start of ISD to reactivation were relatively long (3-182 months; median, 66 months).The incidence of HBV reactivation with ISD use was 1.93/100 person-years in patients with RD with resolved HBV infection. No overt hepatitis was observed in the reactivated patients.
Runx1 Is Required for Notch-Induced Specification of Megakaryocyte Development from Early Hematopoietic Stem and Progenitor Cells
Authors: Melanie G Cornejo, Thomas Mercher, Joseph D. Growney, Jonathan Jesneck, Ivan Maillard, Warren S. Pear, Jon Aster, D. Gary Gilliland
Journal: Blood (2008)
Polycomb Group Protein-Mediated Bivalent Domains Regulate Pluripotency of Oct4+ Very Small Embryonic-Like (VSEL) Stem Cells In Adult Bone Marrow
Authors: Dong-Myung Shin, Rui Liu, Wu Wan, Janina Ratajczak, Mariusz Z Ratajczak, Magdalena Kucia
Journal: Blood (2010)
Low Bone Mass in Thalassemia: The Thalassemia Clinical Research Network (TCRN) Experience.
Authors: Maria G. Vogiatzi, Joseph Lane, Martin Fleisher, Eric A. Macklin, Ellen B. Fung, Melanie Kirby, Janet Kwiatkowski, Ingrid Holm, Nancy Olivieri, Elliott Vichinsky, Patricia J. Giardina
Journal: Blood (2004)
Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib
Authors: Jeffrey Jones, Michael Y. Choi, Anthony R. Mato, Richard R. Furman, Matthew S. Davids, Leonard T. Heffner, Bruce D. Cheson, Nicole Lamanna, Paul M. Barr, Herbert Eradat, Ahmad Halwani, Brenda Chyla, Ming Zhu, Maria Verdugo, Rod A. Humerickhouse, Jalaja Potluri, William G. Wierda, Steven E. Coutre
Journal: Blood (2016)
Prognostic Features, Treatments, and Disease-Specific Mortality Among Patients with Diffuse Large B-Cell Lymphoma Over the Age of 75: A Single-Center Retrospective Analysis
Authors: Stephen D. Smith, Craig Okada, Andy I. Chen, Stephen E Spurgeon, Guang Fan, Jennifer B Dunlap, Nicky Leeborg, Rita M. Braziel, Richard T. Maziarz
Journal: Blood (2012)
Arteriography for Lower Gastrointestinal Hemorrhage
Authors: Hung Q. Dam, Thomas B. Kinney
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Impact of Dendritic Cell CD16+ Recovery on Outcome after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation.
Authors: Carme Talarn, Alvaro Urbano-Ispizua, Rodrigo Martino, Montse Batlle, Concha Herrera, Jose Antonio Perez-Simon, Montse Torrebadell, Francesc Fernandez-Aviles, Anna Gaya, Miquel Granell, Pedro Marin, Jordi Sierra, Emili Montserrat
Journal: Blood (2005)